Prevalence of Obesity, Type II Diabetes Mellitus, Hyperlipidemia, and Hypertension in the United States: Findings from the GE Centricity Electronic Medical Record Database
Publication: Population Health Management
Volume 13, Issue Number 3
Abstract
This study analyzed GE Centricity Electronic Medical Record (EMR) data to examine the effects of body mass index (BMI) and obesity, key risk factor components of metabolic syndrome, on the prevalence of 3 chronic diseases: type II diabetes mellitus, hyperlipidemia, and hypertension. These chronic diseases occur with high prevalence and impose high disease burdens. The rationale for using Centricity EMR data is 2-fold. First, EMRs may be a good source of BMI/obesity data, which are often underreported in surveys and administrative databases. Second, EMRs provide an ideal means to track variables over time and, thus, allow longitudinal analyses of relationships between risk factors and disease prevalence and progression. Analysis of Centricity EMR data showed associations of age, sex, race/ethnicity, and BMI with diagnosed prevalence of the 3 conditions. Results include uniform direct correlations between age and BMI and prevalence of each disease; uniformly greater disease prevalence for males than females; varying differences by race/ethnicity (ie, African Americans have the highest prevalence of diagnosed type II diabetes and hypertension, while whites have the highest prevalence of diagnosed hypertension); and adverse effects of comorbidities. The direct associations between BMI and disease prevalence are consistent for males and females and across all racial/ethnic groups. The results reported herein contribute to the growing literature about the adverse effects of obesity on chronic disease prevalence and about the potential value of EMR data to elucidate trends in disease prevalence and facilitate longitudinal analyses. (Population Health Management 2010;13:151–161)
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Reaven GM. Role of insulin resistance in human disease. The Banting lectureDiabetes1988371595-1607. 1. Reaven GM. Role of insulin resistance in human disease. The Banting lecture. Diabetes 1988;37:1595–1607.
2.
Alberti KGZimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultationDiabet Med199815539-553. 2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553.
3.
Balkau BCharles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)Diabet Med199916442-443. 3. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442–443.
4.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA20012852486-2497. 4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
5.
Alberti KZimmet PShaw J. Metabolic syndrome—A new world-wide definition. A consensus statement from the International Diabetes FederationDiabet Med200623469-480. 5. Alberti K, Zimmet P, Shaw J. Metabolic syndrome—A new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469–480.
6.
Lawlor DDavey Smith GDEbrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health StudyDiabetologia20064941-48. 6. Lawlor D, Davey Smith GD, Ebrahim S. Does the new International Diabetes Federation definition of the metabolic syndrome predict CHD any more strongly than older definitions? Findings from the British Women's Heart and Health Study. Diabetologia 2006;49:41–48.
7.
Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidenceDiabet Care2005281769-1778. 7. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabet Care 2005;28:1769–1778.
8.
Malik SNathan DWong S et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adultCirculation20041101245-1250. 8. Malik S, Nathan D, Wong S, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adult. Circulation 2004;110:1245–1250.
9.
Meigs JBWilson PWFNathan DM et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring StudiesDiabetes2003522160-2167. 9. Meigs JB, Wilson PWF, Nathan DM, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003;52:2160–2167.
10.
Hanley AJGKarter AJWilliams K et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: The insulin resistance atherosclerosis studyCirculation20051123713-3721. 10. Hanley AJG, Karter AJ, Williams K, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: The insulin resistance atherosclerosis study. Circulation 2005;112:3713–3721.
11.
Hong YJin XMo J et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality. Results of prospective analysis for the atherosclerosis risk in communities studyJ Intern Med2007262113-123. 11. Hong Y, Jin X, Mo J, et al. Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality. Results of prospective analysis for the atherosclerosis risk in communities study. J Intern Med 2007;262:113–123.
12.
Meigs JBRutter MKSullivan LM et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndromeDiabetes Care2007301219-1225. 12. Meigs JB, Rutter MK, Sullivan LM, et al. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007;30:1219–1225.
13.
Park YShu SPalianiappen L et al. The metabolic syndromeArch Int Med2003163427-436. 13. Park Y, Shu S, Palianiappen L, et al. The metabolic syndrome. Arch Int Med 2003;163:427–436.
14.
National Heart, Lung, and Blood Institute and Boston University. Framingham heart studyhttp://www.nhlbi.nih.gov/about/framingham/index.htmlDecember122007. 14. National Heart, Lung, and Blood Institute and Boston University. Framingham heart study. Available at: http://www.nhlbi.nih.gov/about/framingham/index.html. Accessed December 12, 2007.
15.
Kannel WBFeinleib MMcNamara PMGarrison RJCastelli SP. An investigation of coronary heart disease in families: The Framingham Offspring StudyAm J Epidemiol1979110281-290. 15. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli SP. An investigation of coronary heart disease in families: The Framingham Offspring Study. Am J Epidemiol 1979;110:281–290.
16.
Bays HEChapman RHGrandy Sfor the SHIELD Investigators' Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveysInt J Clin Pract200761737-747. 16. Bays HE, Chapman RH, Grandy S, for the SHIELD Investigators' Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract 2007;61:737–747.
17.
McTigue KLarson JCValoski A et al. Mortality and cardiac and vascular outcomes in extremely obese womenJAMA200629679-86. 17. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 2006;296:79–86.
18.
Sturm R. Increases in morbid obesity in the USA: 2000–2005Public Health2007121492-496. 18. Sturm R. Increases in morbid obesity in the USA: 2000–2005. Public Health 2007;121:492–496.
19.
Brixner DSaid QKirkness COberg BBen–Joseph ROderda G. Assessment of cardiometabolic risk factors in a national primary care electronic health record databaseValue in Health200710S29-S36. 19. Brixner D, Said Q, Kirkness C, Oberg B, Ben–Joseph R, Oderda G. Assessment of cardiometabolic risk factors in a national primary care electronic health record database. Value in Health 2007;10:S29–S36.
20.
Gill JChen Y. Quality of lipid management in outpatient care: A national study using electronic health recordsAm J Med Qual200823375-381. 20. Gill J, Chen Y. Quality of lipid management in outpatient care: A national study using electronic health records. Am J Med Qual 2008;23:375–381.
21.
Oderda GBrixner DLieberman M. Comparison of EMR data to US national dataPaper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)10th Annual European CongressOctober20–232007DublinIreland. 21. Oderda G, Brixner D, Lieberman M. Comparison of EMR data to US national data. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Congress; October 20–23, 2007; Dublin, Ireland.
22.
Grundy SMCleeman JIDaniels SR et al. Management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific StatementCirculation20051122735-2752. 22. Grundy SM, Cleeman JI, Daniels SR, et al. Management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752.
23.
Chobanian AVBakris GLBlack HRCushman WCGreen LAIzzo JL Jrthe National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 reportJAMA20032892560-2572. 23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560–2572.
Information & Authors
Information
Published In
Copyright
Copyright 2010, Mary Ann Liebert, Inc.
History
Published online: 23 June 2010
Published ahead of print: 3 June 2010
Published in print: June 2010
Authors
Author Disclosure Statement
Dr. Haas is employed by Ethicon Endo-Surgery, Inc. Ethicon Endo-Surgery, Inc., funded this study, and it contracted with all other authors listed on this article. Drs Crawford, Cote, Couto, Daskiran, Gunnarsson, Haas, Nigam, and Schuette, and Ms. Haas disclosed no other financial ties or conflicts of interest.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.